A Real-World Study on the Use, Effectiveness, and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression: INTEGRATE Study.
Advances in therapy May 1, 2025 Patricio Molero, Angela Ibañez, Javier de Diego-Adeliño et al. 8 citations
In a real-world Spanish study of 189 adults with treatment-resistant depression, esketamine nasal spray led to response or remission in 80.4% of patients during the induction phase and 90% during the maintenance phase. Remission rates rose from 9.5% in induction to 38.3% in maintenance. Over a quarter of patients (28.0%) reported symptom improvement within 24 hours. Most adverse events were mild and decreased over time, especially in the first four weeks. The findings suggest esketamine nasal spray is an effective and safe option for treatment-resistant depression.